pathogen
resist
develop
cost
major
challeng
current
approach
antivir
therapi
high
error
rate
rna
synthesi
reversetranscript
confer
genom
plastic
enabl
remark
adapt
rna
virus
antivir
intervent
howev
properti
coupl
fundament
constraint
includ
limit
size
inform
avail
manipul
complex
host
support
viral
replic
accordingli
rna
virus
employ
variou
mean
extract
maximum
util
inform
limit
genom
correspondingli
may
leverag
effect
hostori
therapi
hostori
approach
becom
increasingli
feasibl
increas
avail
bioactiv
compound
recent
advanc
immunotherapi
precis
medicin
particularli
genom
edit
target
deliveri
method
rnai
turn
one
drive
forc
behind
innov
increasingli
detail
understand
evolutionarili
divers
hostviru
interact
key
concern
emerg
field
neovirolog
review
examin
biotechnolog
solut
diseas
sustain
issu
time
leverag
properti
rna
dna
virus
develop
coevolut
host
humaninfect
virus
rna
virus
harbour
singlestrand
rna
ssrna
genom
includ
establish
pathogen
hiv
dengu
viru
denv
highprofil
emerg
pathogen
decad
eg
zika
viru
zikv
sarscoronaviru
sarscov
avian
influenza
reemerg
pathogen
includ
measl
viru
mv
everi
pathogen
prioritis
recent
r
blueprint
furthermor
climat
changerel
factor
like
drive
chang
futur
dispers
transmiss
virus
includ
mosquitoborn
virus
denv
zikv
diseas
burden
associ
mani
humaninfect
rna
viru
speci
larg
grow
yet
five
us
food
drug
administr
fda
approv
antivir
avail
nearli
target
viru
protein
tabl
virusori
approach
efficaci
genet
divers
virus
often
restrict
treatment
particular
speci
serotyp
tabl
furthermor
antivir
often
costli
ultim
suscept
escap
mutant
select
simpl
point
substitut
often
respons
treatment
failur
fit
cost
associ
harbour
substitut
may
trivial
absorb
escap
strain
upon
accumul
compensatori
adapt
tenofovir
exampl
highli
effect
singleregimen
treatment
chronic
hepat
b
infect
retrotranscrib
viru
characteris
consider
genet
heterogen
simultan
impos
potent
viral
suppress
high
barrier
escap
reduc
replic
fit
escap
strain
despit
synergis
effect
complex
escap
mutant
harbour
multipl
point
substitut
viral
revers
transcriptas
recent
emerg
one
way
enhanc
treatment
efficaci
minimis
viral
escap
deploy
exist
antivir
combin
therapi
strategi
use
extens
current
hiv
eg
tenofoviremtricitabin
hepat
c
viru
hcv
treatment
regimen
increas
number
combin
increas
height
escap
barrier
proport
increas
treatment
cost
advers
effect
counterind
make
strategi
one
ever
compound
challeng
ultim
remain
expos
core
problem
viral
resist
treatment
failur
continu
need
develop
addit
therapi
realis
cost
play
strength
viru
evolut
oblig
intracellular
parasit
virus
must
subvert
key
resourc
permiss
host
order
replic
subvert
multifunct
host
protein
confer
signific
fit
advantag
enabl
rna
virus
effici
execut
multipl
step
replic
strategi
time
featur
like
conserv
within
lineag
serv
foci
evolutionari
converg
virus
similar
host
rang
purifi
select
elimin
step
render
less
effici
nevertheless
ideal
target
pathogen
virus
includ
also
vital
host
therebi
limit
option
antivir
adapt
drive
costli
evolutionari
innov
part
similarli
potenti
advers
effect
limit
option
target
host
protein
therapeut
therapeut
drug
avail
togeth
recent
advanc
area
includ
immunotherapi
precis
medicin
begin
allevi
constraint
hostori
approach
significantli
mani
technolog
aros
examin
evolutionarili
divers
hostviru
immun
interact
increasingli
uncov
advent
mass
nextgener
genom
sequenc
machin
learningassist
metagenom
analysi
technolog
furthermor
interact
increasingli
found
perform
crucial
role
throughout
biospher
case
crispr
ca
bacteri
immun
system
protein
use
genom
edit
hostviru
interact
often
employ
uniqu
protein
unknown
function
review
examin
hostviru
evolut
may
leverag
toward
solv
diseas
sustain
issu
time
multitask
multifunct
host
protein
antivir
therapeut
target
method
target
protein
vaccin
design
neovirolog
emerg
sourc
biotechnolog
innov
discuss
rna
retrotranscrib
viru
genom
highli
versatil
error
occur
order
magnitud
frequent
highord
eukaryot
combin
rapid
replic
cycl
imbu
virus
two
key
strength
enorm
genet
divers
rapid
escap
mutant
select
nevertheless
process
enabl
remark
genom
plastic
also
appear
limit
incorpor
new
inform
achiev
favor
host
manipul
exist
invers
relationship
viral
genom
size
mutat
rate
larg
coronavirus
known
rna
viru
famili
possess
exonucleas
proofread
activ
thu
probabl
acquir
lethal
mutat
increas
function
polymeras
infidel
genom
size
suggest
lengthen
genom
accommod
larger
repertoir
gene
product
better
manipul
host
come
consider
fit
tradeoff
rna
virus
inde
except
extrem
small
circular
ssdna
virus
rna
viru
genom
typic
far
shorter
dna
viru
genom
averag
size
vs
kb
respect
maxim
size
vs
kb
encod
fewer
protein
vs
figur
result
variou
rna
virus
toler
certain
gene
substitut
eg
recombin
report
strain
segment
genom
virus
poorli
toler
addit
new
genet
inform
correspondingli
mutagen
nucleosid
analogu
exhibit
broadspectrum
antivir
activ
increas
error
rate
genom
synthesi
nascent
viral
particl
effect
reduc
optim
genom
length
viru
product
infect
threshold
viabil
therebi
drive
popul
extinct
therefor
core
strength
rna
viru
evolut
aris
natur
genet
materi
errorpron
mode
replic
appear
intract
coupl
limit
size
inform
avail
subvert
complex
host
rna
viru
evolut
attempt
resolv
inform
economi
paradox
extens
employ
function
genom
secondari
structur
noncod
region
genom
segment
compress
eg
rna
edit
overprint
frameshift
read
gene
product
pleiotropi
multifunction
eg
intrins
disord
protein
yet
anoth
way
manipul
host
cell
factor
multiinteract
multifunct
hub
cellular
activ
wherebi
singl
viral
gene
product
subvert
singl
host
factor
achiev
net
favor
control
numer
cellular
process
enabl
viru
extract
maximum
util
inform
limit
genom
minim
inform
cost
multipli
effect
across
sever
viral
andor
host
gene
product
may
enabl
viru
extract
substanti
return
invest
term
replic
fit
despit
facilit
viral
infect
solut
inform
economi
paradox
cut
way
imbric
depend
multifunct
host
protein
variou
key
replic
step
creat
vulner
may
exploit
highli
efficaci
antivir
therapi
exampl
deni
host
protein
viru
may
disrupt
multipl
key
element
replic
strategi
protein
repres
foci
evolutionari
converg
therapi
may
yield
robust
broadspectrum
antivir
activ
degre
innov
requir
circumv
therapi
especi
case
rna
virus
inform
barrier
realis
innov
may
high
escap
mutant
emerg
may
forc
overcom
multipl
defici
simultan
suffer
compound
fit
penalti
process
furthermor
hostori
approach
present
much
larger
list
potenti
therapeut
target
dozen
gene
product
produc
humaninfect
rna
virus
mani
challeng
target
first
instanc
genet
divers
intrins
protein
disord
given
higher
fidel
dna
versu
rna
replic
host
therapeut
target
may
prove
resili
certain
mechan
viral
resist
altogeth
advantag
may
reduc
antivir
develop
cost
long
term
allow
greater
treatment
access
faster
develop
futur
therapi
host
protein
suffici
multifunct
might
present
viabl
therapeut
substrat
canvass
potenti
therapeut
target
multifunct
human
protein
identifi
date
use
interrog
avail
protein
interact
data
figur
strikingli
experiment
determin
interact
least
one
viral
protein
supplementari
tabl
interact
least
one
ssrna
viral
protein
highlight
multifunct
host
protein
repres
key
ssrna
viral
manipul
target
three
highli
multifunct
host
protein
target
greatest
divers
ssrna
viru
famili
follow
heatshock
protein
polyadenylatebind
protein
figur
protein
appear
serv
key
driver
converg
divers
humaninfect
virus
suggest
potenti
target
broadspectrum
antivir
addit
target
signific
interest
includ
alphaenolas
heatshock
protein
also
term
heterogen
nuclear
ribonucleoprotein
k
hnrnpk
histon
acetyltransferas
hat
vimentin
vitamin
k
epoxid
reductas
complex
subunit
tumor
antigen
figur
tabl
divers
rna
virus
target
protein
well
possibl
therapeut
avenu
discuss
measl
viru
extrem
contagi
virul
pathogen
undergo
recent
global
resurg
nonstructur
v
protein
target
singl
largest
number
highli
multitask
human
protein
vimentin
hnrnpk
figur
addit
v
establish
role
suppress
multipl
compon
host
interferon
ifn
signal
interact
may
allow
mv
interfac
cytoskeleton
vimentin
subvert
numer
host
cell
process
includ
cell
cycl
hnrnpk
protein
translat
rna
metabol
hnrnpk
transcript
protein
express
v
produc
edit
p
gene
transcript
also
overlap
c
gene
largest
number
amino
acid
substitut
wildtyp
mv
attenu
vaccin
strain
occur
within
pvc
gene
region
suggest
chang
region
serv
import
basi
natur
attenu
sinc
attenu
mv
strain
possess
limit
capac
revers
mv
strain
engin
harbour
defect
v
bind
host
protein
may
suitabl
design
vaccin
candid
discuss
follow
section
repurpos
exist
hosttarget
bioactiv
compound
antivir
may
also
yield
therapeut
result
accessori
protein
viral
infect
factor
vif
also
crucial
suppress
host
immun
target
three
highli
multitask
heatshock
protein
figur
suggest
subvers
cellular
protein
qualiti
control
pathway
hspmediat
gene
express
vital
replic
cycl
accordingli
inhibitor
tanespimycin
tabl
recent
shown
inhibit
transcript
suppress
viral
rebound
humanis
mous
model
although
inhibitor
encount
efficaci
toxic
issu
clinic
trial
anticanc
therapi
aminoxyron
novel
firstinclass
inhibitor
appear
allevi
issu
efficaci
antivir
antiretrovir
therapeut
yet
studi
inhibitor
tabl
repres
addit
avenu
effect
hostori
antiretrovir
therapi
also
yet
explor
tat
transactiv
regulatori
protein
requir
effici
viral
gene
transcript
target
hat
figur
latter
protein
manipul
two
addit
protein
viral
protein
r
vpr
pol
dna
polymeras
well
transactiv
regulatori
protein
tax
human
tlymphotrop
viru
htlv
figur
plausibl
repres
conserv
mechan
host
subvers
hat
histon
deacetylas
hdac
crucial
effector
epigenet
modul
gene
express
connect
larg
number
cell
signal
input
transcript
output
histon
posttransl
modif
hat
hdac
inhibitor
shown
suppress
viral
transcript
kill
reactiv
latent
viru
shockandkil
respect
suggest
epigenet
remodul
host
gene
activ
except
import
replic
strategi
retrovirus
altern
retrovir
protein
may
block
usurp
enzymat
activ
hat
direct
acetyl
viral
host
protein
suggest
tat
interact
hat
protein
tat
vpr
pol
figur
togeth
larg
number
hat
inhibitor
current
avail
tabl
expand
possibl
target
hat
hostori
antiretrovir
therapi
influenza
viru
iav
engag
four
gene
product
manipul
two
highli
multifunct
host
protein
target
virul
factor
transcript
cap
rnadepend
rna
polymeras
rdrp
alphaenolas
target
well
vrnp
nuclear
export
figur
protein
avian
influenza
strain
well
reportedli
bind
modul
caspasemedi
apoptosi
addit
impair
replic
inhibitor
reportedli
inhibit
iav
replic
without
appar
cytotox
vitro
interest
examin
whether
effect
translat
vivo
use
nextgener
inhibitor
tabl
influenza
viru
togeth
sarscov
multipl
flavivirus
also
target
alphaenolas
enzym
role
glycolysi
cell
growth
immun
figur
novel
inhibitor
enoblock
recent
develop
interest
properti
block
nonglycolyt
function
alphaenolas
tabl
drug
show
promis
treat
obes
anim
model
antivir
effect
remain
unexplor
warrant
studi
potenti
hostori
antivir
approach
iav
viral
infect
similarli
commit
four
protein
manipul
hnrnpk
figur
sindbi
viru
sinv
reveal
multifunct
host
protein
crucial
replic
strategi
coimmunoprecipit
experi
suggest
hnrnpk
associ
sinv
polyprotein
process
product
methyl
guanylyltransferas
helicaseproteas
regulatori
compon
may
requir
viral
transcript
togavirida
member
includ
semliki
forest
viru
sfv
chikungunya
viru
chikv
also
manipul
hnrnpk
figur
suggest
host
protein
serv
multipl
evolutionarili
conserv
role
togaviru
replic
hint
potenti
therapeut
rout
togavirus
current
select
hnrnpktarget
drug
avail
tabl
hnrnpk
also
tumor
suppressor
mutat
constitut
downregul
hnrnpk
associ
tumorigenesi
nevertheless
shortterm
therapeut
target
hnrnpk
antivir
strategi
yet
explor
viral
infect
often
induc
cytoskelet
remodel
result
cytopath
morpholog
includ
syncytia
tumorlik
aggreg
cell
treat
actin
depolymeris
agent
cytochalasin
show
drastic
reduct
product
numer
virus
figur
vimentin
report
play
key
role
replic
complex
assembl
modul
viral
protein
express
level
denv
hcv
infect
respect
withaferin
target
solubl
form
vimentin
tabl
anticanc
properti
although
effect
vimentintarget
drug
context
infect
yet
extens
studi
numer
flavivirus
includ
denv
hcv
tbev
alkv
kunvwnv
manipul
alphaenolas
figur
enzym
mani
function
includ
catalys
penultim
step
atp
synthesi
via
glycolysi
virus
often
reprogram
cellular
metabol
pathway
denv
drastic
increas
rate
glycolysi
support
replic
metabol
acidosi
often
associ
sever
diseas
may
correl
subcellular
redistribut
viral
protein
compromis
host
stress
respons
thu
denvinfect
patient
simultan
hyperglycaem
eg
diabet
greater
risk
sever
diseas
accordingli
inhibit
glycolysi
impair
replic
denv
flavivirus
vitro
context
would
interest
examin
whether
alphaenolas
inhibitor
tabl
block
nonglycolyt
function
alphaenolas
mention
previous
may
block
subvers
key
enzym
flavivirus
vivo
one
unexpect
multipl
viral
target
enzym
highli
express
liver
crucial
activ
blood
clot
factor
rel
fewer
rna
virus
target
figur
target
sever
dna
virus
includ
hepatotrop
epsteinbarr
viru
would
interest
examin
effect
infect
virus
context
treatment
vitamin
k
drug
warfarin
tabl
multifunct
ubiquitin
ubiquitinlik
modifi
undergo
coval
noncoval
associ
protein
exert
plethor
effect
function
abund
subcellular
distribut
thu
manipul
ubiquitin
ubiquitinlik
posttransl
modif
machineri
proteasom
also
enabl
virus
subvert
multipl
cellular
process
inde
multitask
host
protein
examin
undergo
extens
posttransl
modif
numer
multitask
protein
ubiquitinproteasom
system
well
ubiquitin
ubiquitinlik
modifi
key
target
multipl
virus
target
includ
proteasom
regulatori
subunit
ubiquitinprotein
ligas
chip
modul
activ
numer
protein
chaperon
includ
small
ubiquitinlik
modifierconjug
enzym
regul
numer
cellular
function
includ
cell
cycl
modifi
tabl
supplementari
tabl
numer
inhibitor
proteasom
ubiquitin
enzym
deubiquitin
enzym
current
clinic
trial
approv
use
anticanc
agent
therapeut
modul
ubiquitinproteasom
system
may
present
indirect
method
target
multitask
protein
otherwis
undrugg
present
tabl
therapeut
target
host
protein
converg
variou
cellular
process
elicit
unwant
effect
challeng
familiar
virus
exploit
protein
first
instanc
yet
success
also
impli
sound
antivir
strategi
illustr
multifunct
host
protein
druggabl
human
multitask
protein
annot
francoserrano
et
al
alreadi
target
known
compound
compar
human
protein
list
uniprot
also
suggest
potenti
repurpos
exist
drug
hostori
antivir
therapi
tabl
sinc
virus
typic
infect
replic
best
limit
set
host
tissu
deliv
therapi
specif
tissu
may
mitig
advers
effect
synthet
lipid
nanoparticl
lnp
protect
deliv
small
rna
rnaibas
therapi
well
synthet
vaccin
bioactiv
compound
modifi
virus
viruslik
particl
deliv
rna
interfer
rnai
base
therapi
well
nucleas
dna
gene
therapi
despit
addit
challeng
outlin
technolog
current
appli
deliv
specif
treatment
viral
infect
cardiovascular
diseas
inherit
genet
disord
cancer
immunotherapi
anim
model
human
rnabas
therapi
mirna
sirna
biogenesi
last
eukaryot
common
ancestor
like
possess
rnai
system
utilis
endogen
exogen
noncod
rna
ncrna
rdrp
howev
hostpathogen
interact
shape
rnai
utilis
throughout
eukaryot
diversif
bud
yeast
includ
prototyp
saccharomyc
cerevisia
harbour
endem
dsrna
virus
totivirida
famili
lost
rnai
yeast
lack
virus
retain
rnai
rise
jaw
vertebr
rdrp
lost
ifn
gain
enabl
larg
complex
life
coordin
multifurc
systemwid
respons
infect
eventu
supplant
rnai
primari
antivir
defenc
mechan
anim
nevertheless
ncrna
continu
perform
crucial
role
fundament
mammalian
cellular
process
includ
premrna
process
via
spliceosom
eg
small
nuclear
rna
snrna
small
interf
rna
sirna
microrna
mirna
commonli
appli
current
rnai
biotechnolog
addit
sequenc
tissu
specif
ncrna
function
determin
express
level
posttranscript
process
modif
protein
interact
partner
subcellular
compartmentalis
outlin
mirna
select
express
human
tissu
mirna
current
annot
mirbas
databas
predict
control
transcript
human
proteincod
gene
nucleu
primari
mirna
transcript
process
nt
premirna
microprocessor
complex
compris
rnaseiii
enzym
drosha
latter
also
associ
exosom
play
crucial
role
rna
process
surveil
altern
mirtron
mirna
splice
directli
intron
spliceosom
independ
drosha
transport
premirna
cytosol
droshaindepend
mirna
subset
reportedli
transport
manner
cytosol
rnaseiii
enzym
dicer
excis
nt
doublestrand
mirna
well
endogen
exogen
sirna
fragment
rnaseiii
cleavag
product
characteris
nt
overhang
togeth
monophosphoryl
hydroxy
end
strand
thermodynam
stabl
end
usual
degrad
remain
ssrna
guid
strand
load
onto
argonaut
protein
togeth
ribonucleoprotein
form
rnainduc
silenc
complex
risc
endoribonucleas
activ
cleav
target
rna
achiev
posttranscript
repress
argonaut
protein
repress
express
nondegrad
mechan
exosom
exoribonucleas
requir
full
degrad
risc
cleavag
product
drosophila
intriguingli
serv
crucial
viral
restrict
factor
totivirusharbour
ie
rnaidefici
yeast
exosom
core
compon
associ
identifi
among
highli
multitask
protein
frequent
manipul
humaninfect
virus
protein
includ
core
compon
snrnaprotein
complex
spliceosom
supplementari
tabl
key
mediat
nonsensemedi
mrna
qualiti
control
pathway
recruit
endonucleas
factor
regul
aberr
mrna
decay
interact
may
enabl
evolutionarili
divers
virus
manipul
hostviru
mrna
ncrna
biogenesi
stabil
immun
mechan
potenti
therapeut
applic
rna
posttranscript
control
discuss
yoshinaga
takeuchi
anoth
articl
special
featur
tolllik
receptor
recognis
extracellular
ssrna
short
nt
respect
activ
greater
extent
sequencespecif
manner
irrespect
end
modif
similar
fashion
recognis
extracellular
well
endosom
dsrna
longer
nt
retino
acidinduc
genei
rigi
like
receptor
sens
intracellular
rna
includ
prototyp
rigi
activ
ssrna
short
nt
harbour
dior
triphosphoryl
end
activ
larg
rna
molecul
recognis
rna
short
nt
irrespect
phosphoryl
hydroxyl
end
activ
support
signal
inhibit
rigi
dicer
tlr
rlr
activ
stimul
ifni
express
activ
jakstat
signal
modul
express
hundr
ifnstimul
gene
therebi
place
infect
cell
local
tissu
antivir
state
stimul
ifn
rnai
system
compet
manner
detriment
efficaci
rnaibas
therapeut
rnaibas
approach
antivir
therapi
show
promis
new
familiar
challeng
known
primateinfect
virus
manipul
ifn
signal
howev
despit
nearli
two
decad
studi
role
rnai
specif
immun
defenc
mechan
somat
ifnrespons
tissu
remain
controversi
ifnand
rnaimedi
immun
incompat
humaninfect
virus
would
like
subject
weak
specif
rnaimedi
immun
select
pressur
suggest
dormant
immun
function
mammalian
rnai
system
could
reengin
futur
antivir
immunotherapeut
strategi
altern
gut
microbiom
crucial
regul
immun
homeostasi
tcell
activ
predict
treatment
outcom
cancer
immunotherapi
might
genet
modifi
secret
therapeut
small
rna
rnaibas
strategi
could
use
modul
host
immun
programm
select
revers
block
express
key
multifunct
host
protein
near
virusinfect
tissu
therebi
multipli
regul
viral
replic
discuss
earlier
first
rnai
patent
file
end
sirnabas
mirnabas
therapeut
patent
file
unit
state
anticanc
applic
follow
viral
infect
inflammatori
disord
present
us
nation
librari
medicin
list
mirna
sirna
rnai
intervent
clinic
trial
underway
complet
sever
trial
involv
patisiran
becam
first
rnaibas
therapeut
approv
us
fda
patisiran
lnpencapsul
sirna
sirnalnp
deliv
hepatocyt
transient
induc
rnaimedi
silenc
wildtyp
mutant
transthyretin
mrna
prior
infus
patient
receiv
combin
oral
acetaminophen
intraven
corticosteroid
histamin
receptor
antagonist
yet
infusionrel
reaction
remain
one
frequent
advers
event
antagonist
immun
receptor
outlin
may
suppress
ifn
stimul
circul
sirnalnp
breakdown
product
reduct
immunogen
may
achiev
rna
modif
pseudouridyl
encapsul
sirna
exosom
vesicl
biolog
nanoparticl
ad
advantag
industri
scaleup
use
bioreactor
altern
approach
may
leverag
abil
viral
evolut
inhibit
host
immun
exampl
revers
incorpor
exogen
rna
ribonucleoprotein
complex
compos
protein
evolv
inhibit
ifn
signal
could
simultan
yield
therapeut
rna
deliveri
ifn
suppress
remark
sirnalnp
cocktail
perfect
complementar
ebola
viru
ebov
rna
report
confer
protect
nonhuman
primat
administ
late
day
postleth
challeng
nevertheless
nucleotid
escap
mutant
genet
variat
ebov
strain
differ
geograph
locat
necessit
accur
uptod
sequenc
data
circul
strain
order
continu
gener
effect
sirna
cocktail
recent
protocol
employ
minion
portabl
sequenc
develop
enabl
direct
sequenc
intact
rna
viru
genom
iav
first
time
direct
sequenc
field
ebov
strain
would
drastic
reduc
current
develop
time
new
sirnalnp
nevertheless
improv
sequenc
technolog
requir
accur
costeffect
routin
sequenc
substanti
loweryield
genet
divers
field
strain
virusori
treatment
problem
viral
resist
rnabas
therapeut
perhap
best
illustr
hiv
liu
et
al
produc
doubl
long
hairpin
rna
dlhrna
process
endogen
rais
four
antihiv
shrna
direct
gag
tat
vpu
env
transcript
despit
cell
stabli
express
dlhrna
togeth
combinatori
target
approach
use
viru
produc
singl
molecular
clone
nucleotid
escap
mutant
emerg
integr
prolifer
day
postinfect
notabl
howev
viral
transcript
knockdown
variabl
incomplet
therebi
creat
environ
suitabl
escap
mutant
propag
select
rnai
target
viru
even
highli
conserv
well
incorpor
larger
number
shrna
cocktail
may
better
resist
escap
mutant
yield
longerlast
efficaci
futur
virusori
rna
therapi
engag
viru
term
full
view
evolutionari
strength
one
altern
approach
sequest
host
mirna
crucial
viral
replic
highli
express
liver
necessari
hcv
replic
target
two
hostori
therapeut
miravirsen
miravirsen
show
efficaci
advers
effect
clinic
trial
show
promis
efficaci
remain
subject
clinic
hold
advers
effect
besid
safeti
clear
limit
medic
relev
virus
use
host
mirna
key
element
replic
strategi
one
solut
engin
virus
harbour
endogen
mirnatarget
sequenc
yield
recombin
virus
resembl
wildtyp
greatli
reduc
pathogen
restrict
tissu
tropism
impair
replic
fit
potenti
use
vaccin
use
polioviru
pv
replic
primarili
pharynx
gastrointestin
tract
caus
sever
neurolog
diseas
barn
et
al
first
demonstr
recombin
pv
harbour
complementari
sequenc
murin
brainspecif
sever
compromis
abil
replic
within
tissu
sequenc
substitut
sequenc
complementari
ubiquit
express
mirna
pv
replic
reduc
indic
mirna
may
use
control
tissu
tropism
notabl
similar
effect
obtain
mice
render
genet
unrespons
ifn
nevertheless
gener
protect
antibodi
reinfect
time
ld
wildtyp
pv
approach
recent
use
yee
et
al
toward
develop
live
attenu
vaccin
enteroviru
similar
result
also
obtain
kelli
et
al
use
coxsackieviru
major
mice
inocul
recombin
viru
harbour
tissuespecif
mirnatarget
sequenc
show
greatli
reduc
morbid
mortal
day
postinfect
benitez
et
al
show
mice
inocul
much
time
ld
iav
also
modifi
harbour
murin
mirnatarget
sequenc
remain
asymptomat
day
postinfect
mice
also
ifnunrespons
confirm
mammal
principl
elicit
highli
effect
rnaimedi
antivir
respons
immunolog
memori
evolutionari
divers
virus
absenc
ifni
nevertheless
virus
harbour
similar
modif
shown
mix
result
contrast
earlier
work
coxsackieviru
kelli
et
al
found
vesicular
stomat
viru
engin
contain
variou
host
mirnatarget
sequenc
larg
resist
mirnamedi
restrict
nevertheless
decreas
neurotox
observ
also
preserv
viru
oncolyt
activ
properti
crucial
cancer
immunotherapi
applic
denv
success
restrict
hematopoiet
cell
introduc
four
target
site
although
viru
quickli
revert
continu
prolifer
low
level
excis
four
site
sinc
appear
clear
pattern
might
explain
dispar
effect
viru
speci
addit
work
remain
order
use
recombin
mirtarget
virus
routin
therapeut
use
nearli
year
elaps
first
patent
file
realis
approv
rnaibas
therapeut
challeng
remain
come
decad
appear
like
mark
begin
growth
curv
creativ
new
approach
rnabas
therapeut
antivir
immunotherapeut
applic
elicit
humor
well
longlast
cellular
immun
live
attenu
vaccin
effect
therapi
current
avail
typic
produc
passag
viral
isol
permiss
immunedefici
host
embryon
chicken
egg
nonhuman
continu
cell
line
eg
vero
therebi
forc
viral
readapt
loss
virul
origin
host
howev
basi
attenu
usual
illdefin
speci
clinic
isol
readili
amen
current
vitro
cultur
method
eg
noroviru
often
fail
recapitul
essenti
element
viral
replic
cycl
pathogenesi
furthermor
attenu
strain
often
compromis
immun
adjuv
requir
stimul
antigen
upon
inocul
collect
challeng
increas
product
cost
mani
vaccin
limit
detail
studi
number
virus
safe
effect
live
vaccin
produc
address
product
cost
rnai
crispr
recent
appli
attempt
engin
cell
produc
greater
viral
yield
use
genomewid
rnai
screen
cell
valid
vero
cell
line
approv
vaccin
develop
van
der
sanden
et
al
identifi
sever
gene
knockdown
drastic
increas
yield
multipl
pv
enteroviru
rotaviru
strain
howev
effect
viral
replic
recapitul
followup
reason
discrep
result
remain
unclear
challeng
evid
remain
engin
cell
line
support
greater
viral
yield
vaccin
deploy
altern
approach
genet
reprogram
cell
deriv
host
speci
serv
natur
reservoir
viru
one
advantag
approach
like
greater
amen
previous
uncultiv
pooryield
virus
cultiv
ex
vivo
addit
result
strain
like
preserv
replic
compet
upon
inocul
therebi
elicit
stronger
immun
absenc
adjuv
challeng
remain
howev
identifi
part
cell
cultur
method
modifi
gener
broad
permiss
high
titr
greatli
reduc
virul
simultan
obviou
candid
includ
gene
restrict
viral
replic
dispens
cell
surviv
ifn
gene
signal
compon
potenti
certain
multifunct
protein
taken
logic
conclus
possibl
genet
engin
immunenul
human
cell
substrat
within
passag
viru
free
virul
factor
target
immun
select
pressur
way
strain
emerg
like
exhibit
strong
antigen
sever
degrad
mechan
host
immun
antagon
approach
may
also
prove
use
context
virus
caus
sever
diseas
primarili
cytokin
hyperactiv
addit
modif
hostori
approach
may
improv
vaccin
yield
safeti
may
includ
elimin
proapoptot
gene
limit
virusinduc
program
cell
death
increas
viral
titr
cultur
system
may
improv
better
repres
threedimension
microarchitectur
host
tissu
featur
necessari
effici
viral
replic
organoid
stem
cellderiv
tissu
repres
one
approach
recent
intensifi
examin
human
lung
organoid
demonstr
recapitul
key
properti
rsv
pathogenesi
human
intestin
epithelium
develop
previous
uncultiv
noroviru
addit
incorpor
multipl
tissuespecif
mirnatarget
sequenc
within
attenu
viral
genom
may
improv
vaccin
safeti
impair
abil
replic
within
inflammationsensit
irreplac
tissu
invers
strategi
may
use
help
guid
infect
certain
tissu
oncolyt
virus
case
cancer
immunotherapi
anoth
safeti
featur
could
involv
drugselect
kill
switch
wherebi
key
viral
protein
fuse
protein
destabilis
domain
viral
fusion
protein
rescu
proteasom
degrad
presenc
drug
effici
degrad
upon
remov
therebi
yield
condit
replicationincompet
strain
come
decad
appear
like
see
two
key
transit
empir
design
vaccin
virus
pathogen
import
tool
biotechnolog
million
known
speci
earth
virus
like
ancient
prolif
least
virion
estim
exist
today
sampl
fraction
divers
hostviru
interact
alreadi
result
groundbreak
biotechnolog
includ
biomolecul
bioactiv
compound
deliveri
system
rnaimedi
antivir
therapi
genet
engin
use
zinc
finger
nucleas
talen
widerang
applic
antivir
therapi
vaccin
develop
immunotherapi
regen
medicin
environment
scienc
numer
field
neovirolog
emerg
field
aim
trajectori
innov
systemat
characteris
role
virus
viralmedi
process
entir
live
biospher
unexplor
genet
divers
virus
unlock
improv
sequenc
technolog
big
data
analysi
molecular
basi
hostviru
interact
evolutionari
relationship
highli
diverg
speci
becom
clearer
one
area
interest
increas
number
nucleocytoplasm
larg
dna
virus
ncldv
discov
prokaryot
protist
invertebr
host
soil
water
includ
two
amoeb
pathogen
pandoraviru
harbour
largest
known
viral
genom
mb
mimiviru
emerg
human
pathogen
harbour
mb
genom
stark
contrast
rna
virus
giant
dna
virus
appear
capabl
acquir
addit
inform
without
clear
bound
present
altern
solut
inform
economi
paradox
virus
also
suggest
readili
gener
gene
de
novo
complet
genom
sequenc
virus
current
avail
numer
protein
encod
vast
viral
genom
entir
novel
process
de
novo
gener
viral
gene
har
could
support
effort
direct
evolut
new
use
biolog
function
nucleocytoplasm
larg
dna
virus
protein
infer
function
reveal
interest
pattern
recent
discov
ncldv
encod
full
set
eukaryotelik
histon
dna
polymeras
potenti
place
root
eukaryot
clade
ancient
ncldvlike
viru
may
respons
origin
eukaryot
nucleu
subsequ
eukaryot
multicellular
coupl
program
cell
death
may
emerg
ancient
antivir
defenc
mechan
possibl
enabl
rise
complex
life
retrovir
element
addit
drive
format
mammalian
placenta
control
hormon
involv
gestat
birth
time
mammal
element
human
genom
also
contain
genet
materi
deriv
virus
retrotranscript
integr
function
thu
despit
strictli
nonliv
virus
radic
shape
live
biospher
understand
process
could
enabl
new
approach
control
basic
function
life
area
improv
understand
hostviru
interact
could
immedi
implic
includ
human
diseas
bioremedi
harm
algal
bloom
climat
chang
contemporari
virus
overwhelmingli
infect
marin
microorgan
turn
estim
ocean
microbiom
daili
infect
signific
effect
carbon
absorpt
ocean
well
global
nutrient
energi
cycl
nevertheless
interact
ocean
virom
microbiom
effect
climat
remain
poorli
characteris
examin
evolutionarili
divers
hostviru
interact
detail
immunolog
virolog
may
provid
effect
solut
human
diseas
also
cost
environment
sustain
issu
time
outlin
review
current
antivir
almost
exclus
target
viru
protein
signific
develop
cost
limit
therapeut
rang
ultim
suscept
escap
mutant
select
despit
intract
limit
inform
size
rna
virus
thorough
problem
solver
often
subvert
multitask
host
protein
achiev
favor
host
subvers
minim
inform
cost
solut
viral
inform
economi
paradox
often
conserv
creat
opportun
leverag
imbric
multidepend
key
host
protein
hostori
antivir
therapi
effect
broadact
ultim
costeffect
although
protein
present
challeng
therapeut
target
hostori
therapi
synergis
increas
therapeut
drug
avail
develop
rnai
precis
medicin
immunotherapi
addit
method
increas
viral
antigen
yet
control
replic
tissu
tropism
increas
number
virus
safe
highli
effect
vaccin
produc
virus
ncldv
appear
readili
acquir
new
inform
subvert
host
fruit
problemsolv
virus
includ
larg
number
protein
uniqu
unknown
biolog
function
influenc
genet
hallmark
virus
extrem
found
human
throughout
live
biospher
expand
examin
evolutionarili
divers
hostviru
interact
diseas
cost
environment
sustain
issu
time
may
remedi
leverag
rather
yield
properti
rna
dna
virus
develop
coevolut
host
